Article

  • The EMBO Journal (1999) 18, 375 - 385
  • doi:10.1093/emboj/18.2.375

Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibition of LIF and IL-6 signal transduction

Sandra E. Nicholson1, Tracy A. Willson1, Alison Farley1, Robyn Starr1, Jian-Guo Zhang1, Manuel Baca1, Warren S. Alexander1, Donald Metcalf1, Douglas J. Hilton1 and Nicos A. Nicola1

  1. The Walter and Eliza Hall Institute of Medical Research and the Cooperative Research Center for Cellular Growth Factors, Parkville, Victoria 3050, Australia

Correspondence to:

Sandra E. Nicholson, E-mail: snicholson@wehi.edu.au

Received 8 September 1998; Accepted 20 November 1998; Revised 20 November 1998


SOCS-1 (suppressor of cytokine signaling-1) is a representative of a family of negative regulators of cytokine signaling (SOCS-1 to SOCS-7 and CIS) characterized by a highly conserved C-terminal SOCS box preceded by an SH2 domain. This study comprehensively examined the ability of several SOCS family members to negatively regulate the gp130 signaling pathway. SOCS-1 and SOCS-3 inhibited both interleukin-6 (IL-6)- and leukemia inhibitory factor (LIF)-induced macrophage differentiation of murine monocytic leukemic M1 cells and LIF induction of a Stat3-responsive reporter construct in 293T fibroblasts. Deletion of amino acids 51–78 in the N-terminal region of SOCS-1 prevented inhibition of LIF signaling. The SOCS-1 and SOCS-3 N-terminal regions were functionally interchangeable, but this did not extend to other SOCS family members. Mutation of SH2 domains abrogated the ability of both SOCS-1 and SOCS-3 to inhibit LIF signal transduction. Unlike SOCS-1, SOCS-3 was unable to inhibit JAK kinase activity in vitro, suggesting that SOCS-1 and SOCS-3 act on the JAK–STAT pathway in different ways. Thus, although inhibition of signaling by SOCS-1 and SOCS-3 requires both the SH2 and N-terminal domains, their mechanisms of action appear to be biochemically different.

  • Keywords:

    • cytokines,
    • JAKs,
    • negative regulators,
    • signal transduction,
    • SOCS